Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia

• Published in: Blood Vol. 101; no. 9; pp. 3386 - 3390
• Main Authors: Matsushima, Takafumi, Handa, Hiroshi, Yokohama, Akihiko, Nagasaki, Jun, Koiso, Hiromi, Kin, Yoshitora, Tanaka, Yoko, Sakura, Tohru, Tsukamoto, Norifumi, Karasawa, Masamitsu, Itoh, Katsuhiko, Hirabayashi, Hisami, Sawamura, Morio, Shinonome, Shogo, Shimano, Shun-ichi, Miyawaki, Shuichi, Nojima, Yoshihisa, Murakami, Hirokazu
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 01.05.2003; The Americain Society of Hematology
• Subjects: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Basophils - pathology; Biological and medical sciences; Bone Marrow - pathology; Bone marrow, stem cells transplantation. Graft versus host reaction; Chromosome Aberrations; Disease Progression; Eosinophilia - epidemiology; Eosinophilia - etiology; Eosinophilia - pathology; Female; Hematologic and hematopoietic diseases; Humans; Japan - epidemiology; Leukemia, Myeloid - epidemiology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Leukocyte Count; Life Tables; Male; Medical sciences; Middle Aged; Myelodysplastic Syndromes - classification; Myelodysplastic Syndromes - epidemiology; Myelodysplastic Syndromes - genetics; Myelodysplastic Syndromes - pathology; Prevalence; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Analysis; Survival Rate; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Japan; Human; Symptomatology; Prevalence; Bone marrow; Malignant hemopathy; Epidemiology; Eosinophilia; Myelodysplastic syndrome; Basophilia
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2002-03-0947

By retrospectively analyzing 288 patients with de novo myelodysplastic syndrome (MDS), we sought to determine the prevalence and clinical characteristics of bone marrow eosinophilia and basophilia that were detected at presentation. Bone marrow eosinophilia and basophilia were defined as a differential count of each cell type exceeding 5.0% and 1.0%, respectively. Of 288 patients with MDS, 36 (12.5%) fulfilled this criterion for bone marrow eosinophilia (MDS-Eos); 34 patients (11.8%) showed basophilia (MDS-Bas), and 11 (3.8%) satisfied both criteria (MDS-EosBas). The remaining 229 patients had neither eosinophilia nor basophilia in their bone marrow (MDS−/−) at presentation. Cytogenetic analysis was carried out on unstimulated bone marrow cells obtained from 264 patients. When the cytogenetic categorization of the IPSS (International Prognostic Scoring System) for MDS was applied, significantly higher numbers of MDS-Eos and MDS-Bas patients had chromosomal abnormalities carrying intermediate or poor prognosis, compared with the MDS−/− patients. Specific chromosomal abnormalities and complex karyotypes were associated with MDS-Eos and/or MDS-Bas. In accordance with these results, the overall survival rate was significantly lower, and the evolution to acute myelogenous leukemia (AML) occurred more frequently in the MDS-Eos and MDS-Bas than in the MDS−/− patients. Multivariate analysis demonstrated that bone marrow basophilia was an independent risk factor for evolution to AML. Our study indicates that bone marrow eosinophilia and basophilia in patients with MDS predict a poorer prognosis.